Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.58 |
| ▸ | ABL1 | P00519 | 7/20 | 0.58 |
| ▸ | RET | P07949 | 5/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.57 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.57 |
| ▸ | FYN | P06241 | 3/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | YES1 | P07947 | 2/20 | 0.57 |
| ▸ | LYN | P07948 | 2/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.57 |
| ▸ | PRKACA | P17612 | 2/20 | 0.57 |
| ▸ | FRK | P42685 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019650 | 0.83 | SRC (0.64) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL15929311 | 0.80 | SRC (0.61) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL3782929 | 0.80 | SRC (0.58) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL22521563 | 0.80 | KDM4E (0.63) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL15471369 | 0.80 | SRC (0.58) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL23055859 | 0.80 | SRC (0.58) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL13019664 | 0.79 | SRC (0.57) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL14617301 | 0.78 | SRC (0.89) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL24735059 | 0.78 | SRC (0.56) | SRCABL1RETPRKD3PRKD2 | |
| SCHEMBL3788404 | 0.78 | SRC (0.57) | SRCABL1RETPRKD3PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-115785100-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-117958271-B | Benzoxazole-like compounds and their use for the preparation of products for increasing plant resistance by closing stomata | 北京大学现代农业研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-115650985-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117958271-A | Benzoxazole-like compounds and their use in the preparation of products for increasing plant resistance by closing stomata | 北京大学现代农业研究院 | 2024-05-03 | — | — | CN | disclosed |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2007373-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | Foldrx Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1973917-A2 | PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | SRC 116/4885ABL1 1/4885RET 848/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | SRC 21/4885ABL1 23/4885RET 1/4885 |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | SRC 23/4885ABL1 25/4885RET 1/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | SRC 21/4885ABL1 23/4885RET 1/4885 |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | SRC 23/4885ABL1 25/4885RET 1/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | SRC 24/4885ABL1 13/4885RET 1/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | SRC 106/4885ABL1 60/4885RET 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.